Figure 3

ABL inhibits miR-155 expression in the ischemic cerebral tissue and BV2 microglial cells. (A) miR-155 at brain tissues of sham, MCAO and MCAO + ABL-treated mice was examined by qRT-PCR. Bars represent means ± SD (n = 6 per group); *P< 0.05 versus sham group; ^#P< 0.05 versus MCAO group. (B) BV2 cells were treated with or without ABL (100 µmol/L) for 24 h prior to OGD. miR-155 at BV2 cells of con, con + ABL, OGD and OGD + ABL-treated groups was examined by qRT-PCR. Bars represent means ± SD from three independent experiments; *P< 0.05 versus con group; ^#P< 0.05 versus OGD group. (C) BV2 cells were transfected with miR-155 (BIC) promoter and PGL3 plasmids, and then treated with or without ABL (100 µmol/L) for 4 h prior to OGD, miR-155 promoter activity was detected by dual luciferase assay. Data are presented as the relative activity ratio of firefly luciferase to Renilla luciferase. *P< 0.05 versus con group.